Alzheimer's disease - Synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts

Journal of Neural Transmission

Volumn 105, Issue 4-5, 1998, Pages 439-461

  Munch G ^a,d   Schinzel, R ^a   Loske, C ^a   Wong, A ^a   Durany, N ^a   Li, J J ^b   Vlassara, H ^b   Smith, M A ^c   Perry, G ^c   Riederer, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b PICOWER INST FOR MEDICAL RESEARCH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Advanced glycation endproducts; Aging; Diabetes; Lipid peroxidation; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE; DNA; FREE RADICAL; GLUCOSE;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CELL DAMAGE; CYCLIZATION; DEHYDRATION; DNA STRAND BREAKAGE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; MEMBRANE DAMAGE; MICROGLIA; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN GLYCOSYLATION; SIGNAL TRANSDUCTION;

AGING; ALZHEIMER DISEASE; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 0042611250     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050069     Document Type: Article

References (125)

1. Anderson AJ, Su JH, Cotman CW (1996) DNA damage and apoptosis in Alzheimers disease - colocalization with c-jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J Neurosci 16: 1710-1719
2. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, Horiuchi S (1995) Macrophage scavenge receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 230: 408-415
3. Arendt T, Holzer M, Grossmann A, Zedlick D, Bruckner MK (1995) Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimers disease. Neuroscience 68: 5-18
4. Arendt T, Rödel L, Gärtner U, Holzer M (1996) Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimers disease. Neuroreport 7: 3047-3049
5. Behl C, Davis JB, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827
6. Behl C, Skutella T, Lezoualch F, Post A, Widmann M, Newton CJ, Holsboer F (1997) Neuroprotection against oxidative stress by estrogens - structure-activity relationship. Mol Pharmacol 51: 535-541
7. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, Nawroth PP (1997) Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96: 2262-2271
8. Blass JP, Baker AC, Ko L, Black RS (1990) Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 47: 864-869
9. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P (1995) Interleukin-1-beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimers and de novo parkinsons disease patients. Neurosci Lett 202: 17-20
10. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16: 271-278
11. Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234
12. Buccala R, Cerami A (1992) Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23: 1-34
13. Busciglio J, Yankner BA (1995) Apoptosis and increased generation of reactive oxygen species in downs syndrome neurons in vitro. Nature 378: 776-779
14. Calingasan NY, Gandy SE, Baker H, Sheu KFR, Kim KS, Wisniewski HM, Gibson GE (1995) Accumulation of amyloid precursor protein-like immunoreactivity in rat brain in response to thiamine deficiency. Brain Res 677: 50-60
15. Calingasan NY, Gandy SE, Baker H, Sheu KFR, Smith JD, Lamb BT, Gearhart JD, Buxbaum JD, Harper C, Selkoe DJ, Price DL, Sisodia SS, Gibson GE (1996) Novel neuritic clusters with accumulations of amyloid precursor protein and amyloid precursor-like protein 2 immunoreactivity in brain regions damaged by thiamine deficiency. Am J Path 149: 1063-1071
16. Christie RH, Freeman M, Hyman BT (1996) Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am J Pathol 14: 8399-8403
17. Citron M, Westaway D, Xia WM, Carlson G, Diehl T, Levesque G, Johnsonwood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, Hyslop PS, Selkoe DJ (1997) Mutant presenilins of Alzheimers disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nature Med 3: 67-72
18. Colaco CALS, Harrington CR (1996) Inhibitors of the Maillard reaction - potential in the treatment of Alzheimers disease. CNS Drugs 6: 167-177
19. Colaco CALS, Ledesma MD, Harrington CR, Avila J (1996) The role of the Maillard reaction in other pathologies - Alzheimers disease. Nephrol Dial Transplant 11: 7-12
20. Cras P, Smith MA, Richey PL, Siedlak SL, Mulvihill P, Perry G (1995) Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 89: 291-295
21. Czech C, Förstl H, Hentschel F, Monning U, Besthorn C, Geiger-Kabisch C, Sattel H, Masters C, Beyreuther K (1995) Apolipoprotein ε-4gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change. Eur Arch Psychiat Clin Neurosci 243: 291-292
22. Dickson DW, Sinicropi S, Yen SH, Ko LW, Mattiace LA, Bucala R, Vlassara H (1996) Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging 17: 733-743
23. Dierks T, Maurer K, Ihl R (1989) Influence of tenilsetam on AEP-300 in Alzheimer's disease. J Neural Transm [P-D-Sect] 1: 49
24. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128
25. Finch CE, Cohen DM (1997) Aging, metabolism, and Alzheimer disease - review and hypotheses. Exp Neurol 143: 82-102
26. Frölich L, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Drug Res 45: 443-336
27. Gärtner U, Holzer M, Heumann R, Arendt T (1995) Induction of p21ras in Alzheimer pathology. Neuroreport 6: 1441-1444
28. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793-807
29. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, Perrino P (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45: 836-840
30. Götz ME, Künig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharm Ther 63: 37-122
31. Gonzalez E, de la Cruz C, de Nicolas R, Egido J, Herrero-Beaumont G (1994) Long-term effect of nonsteroidal anti-inflammatorydrugs on the production of cytokines and otherinflammatory mediators by blood cells of patients withosteoarthritis. Agents Actions 41: 171-178
32. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64: 1216-1223
33. Guzdek A, Stalinska K (1992) Glycated proteins as inducers of acute phase cytokines. Fol Histochem Cytobiol 30: 167-169
34. Haramaki N, Han D, Handelman GJ, Tritschler HJ, Packer L (1997) Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of alpha-lipoic acid. Free Radic Biol Med 22: 535-542
35. Hardy J (1997) Amyloid, the presenilins and Alzheimers disease. Trend Neurosci 20: 154-159
36. Harrington CR, Colaco CA (1994) Alzheimer's disease. A glycation connection. Nature 370: 247-248
37. Hartmann T, Bieger SC, Bruhl B, Tienari PJ, Ida N, Allsop D, Roberts GW, Masters CL, Dotti CG, Unsicker K, Beyreuther K (1997) Distinct sites of intracellular production for Alzheimers disease Aβ-40/42 amyloid peptides. Nature Med 3: 1016-1020
38. Heidrich A, Rösler M, Riederer P (1997) Pharmacotherapy in Alzheimers dementia -treatment of cognitive symptoms - results of new studies. Fortschr Neurol Psychiat 65: 108-121
39. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima N, Lundh ER, Vijay S, Nitecki D (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neuritic outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761
40. Hoyer S (1993) Abnormalities in brain glucose utilization and its impact on cellular and molecular mechanisms in sporadic dementia of Alzheimer type. Ann NY Acad Sci 695: 77-80
41. Hoyer S (1996) Oxidative metabolism deficiencies in brains of patients with Alzheimers disease Acta Neurol Scand 93: 18-24
42. Ihl R, Perisic I, Maurer K, Dierks T (1989) Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). J Neural Transm [P-D Sect]1: 84-85
43. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal P, Vlassara H. (1993) Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-gamma - role in tissue remodeling. J Exp Med 178: 2165-2172
44. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APP(SW) transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965-973
45. Jarrett JT, Lansbury PT Jr (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-1058
46. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C (1997) Transcription factor NFκB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 94: 2642-2647
47. Kimura T, Takamatsu J, Araki K (1995) Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport 6: 866-868
48. Kimura T, Takamatzsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S (1996) Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci Lett 208: 53-56
49. Kohen R, Fanberstein D, Tirosh O (1997) Reducing equivalents in the aging process. Arch Gerontol Geriatr 24: 103-123
50. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814
51. Ledesma MD, Bonay P, Colaco C, Avila J (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269: 21614-21619
52. Ledesma MD, Bonay P, Avila J (1995) Tau protein from Alzheimer's disease patients is glycated at its tubulin-binding domain. J Neurochem 65: 1658-1664
53. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, OBrien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus - a population-based cohort study. Am J Epidemiol 145: 301-308
54. Lieb K, Fiebich BL, Hüll M, Berger M, Bauer J (1997) Potent inhibition of interleukin-6 expression in a human astrocytoma cell line by tenidap. Cell Tissue Res 288: 251-257
55. Li JJ, Voisin D, Quiquerez AL, Bouras C (1994) Differential expression of advanced glycation end-products in neurons of different species. Brain Res 641: 285-288
56. Li JJ, Surini M, Catsicas S, Kawashima E, Bouras C (1995) Age-dependent accumulation of advanced glycosylation end products in human neurons. Neurobiol Aging 16: 69-76
57. Li JJ, Dickson D, Hof P, Vlassara H (1998) Receptors for advanced glycation endproducts in human brain: Role in brain homeostasis. Mol Med 4: 46-60
58. Li YM, Dickson DW (1997) Enhanced binding of advanced glycation endproducts (AGE) by the Apoe4 isoform links the mechanism of plaque deposition in Alzheimers disease. Neurosci Lett 226: 155-158
59. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H (1996) Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 93: 11047-11052
60. Loo DT, Copani A, Pike CJ, Whittemore ER, Walencewicz AJ, Cotman CW (1993) Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90: 7951-7955
61. Lorenzo A, Yankner BA (1996) Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann NY Acad Sci 777: 89-95
62. Maines MD (1988) Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 2: 2557-2568
63. Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, Mandelkow E (1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann NY Acad Sci 777: 96-106
64. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP (1997) Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17: 1046-1054
65. McGeer EG, McGeer PL (1997) Inflammatory cytokines in the CNS - possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications. CNS Drugs 7: 214-228
66. McGeer PL, Rogers J, McGeer EG (1994) Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alzheimer Dis Assoc Disord 8: 149-158
67. McMillian M, Kong LY, Sawin SM, Wilson B, Das K, Hudson P, Hong JS, Bing G (1995) Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem Biophys Res Commun 215: 572-577
68. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA (1997) Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 150: 1933-1939
69. McShea A, Wahl AF, Smith MA (1998) Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer's disease. Med Hypotheses (in press)
70. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U (1997) Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 31: 53-64
71. Miyata T, Hori O, Zhang JH, Yan SD, Ferran L, Lida Y, Schmidt AM (1996) The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of age-beta(2)microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway - implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98: 1088-1094
72. Monnier VM, Cerami A (1981) Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491-493
73. Monnier VM, Sell DR, Nagaraj RH, Miyata S (1991) Mechanisms of protection against damage mediated by the Maillard reaction in aging. Gerontology 37: 152-165
74. Montine TJ, Huang DY, Valentine WM, Amarnath V, Saunders A, Weisgraber KH, Graham DG, Strittmatter WJ (1996a) Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neurol 55: 202-210
75. Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG (1996b) E-4-hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 148: 89-93
76. Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P (1994) The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm [P-D Sect] 8: 193-208
77. Münch G, Mayer S, Michaelis J, Hipkiss AR, Schinzel R, Riederer P, Cunningham AM (1997a) Influence of Advanced Glycosylation Endproducts and AGE - inhibitors on nucleation dependent polymerization of β-amyloid peptide. Biochem Biophys Acta [Mol Bas Dis Sect] 1360: 17-29
78. Münch G, Loske C, Simm A, Schinzel R, Riederer P (1997b) Cytotoxicity of advanced glycation endproducts - protection by antioxidants. Biol Chem 378: S 139
79. Mullarkey CJ, Edelstein D, Brownlee M (1990) Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173: 932-939
80. Namiki M (1988) Chemistry of Maillard reactions: recent studies on the browning reaction mechanism and the development of antioxidants and mutagens. Adv Food Res 32: 115-184
81. Novak M, Kabat J, Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12: 365-370
82. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N (1994) Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 41: 361-371
83. Ott A, Stolk RP, Hofman A, Vanharskamp F, Grobbee DE, Breteler MMB (1996) Association of diabetes mellitus and dementia - the Rotterdam study. Diabetologia 39: 1392-1397
84. Parnetti L, Gaiti A, Polidori MC, Brunetti M, Palumbo B, Chionne F, Cadini D, Cecchetti R, Senin U (1995) Increased cerebrospinal fluid pyruvate levels in Alzheimers disease. Neurosci Lett 199: 231-233
85. Perani D, Grassi F, Sorbi S, Nacmias B, Piacentini S, Piersanti P, Provinciali L, Amaducci L, Fazio F (1997) PET study in subjects from two italian FAD families with APP717 Val to Ile mutation. Eur J Neurol 4: 214-220
86. Praprotnik D, Smith MA, Richey PL, Vinters HV, Perry G (1996) Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Acta Neuropathol 91: 1-5
87. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995) Structure-activity analyses of beta-amyloid peptides - contributions of the beta-25-35 region to aggregation and neurotoxicity. J Neurochem 64: 253-265
88. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 65: 1399-1402
89. Pollard HB, Arispe N, Rojas E (1995) Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell Mol Neurobiol 15: 513-526
90. Price DL, Sisodia SS (1994) Cellular and molecular biology of Alzheimer's disease and animal models. Ann Rev Med 45: 435-446
91. Rapoport SI, Hatanpaa K, Brady DR, Chandrasekaran K (1996) Brain energy metabolism, cognitive function and down-regulated oxidative phosphorylation in Alzheimers disease. Neurodegeneration 5: 473-476
92. Richards GA, van Antwerpen VL, Hunter S, Theron AJ, Vandermerwe CA, Vanderwalt R, Anderson R (1997) Ageing and cigarette smoking are associated with decreased glutathione levels in humans. S Afr J Sci 92: 445-447
93. Roy S, Sen CK, Tritschler HJ, Packer L (1997) Modulation of cellular reducing equivalent homeostasis by alpha-lipoic acid - mechanisms and implications for diabetes and ischemic injury. Biochem Pharmacol 53: 393-399
94. Saada A, Reichert F, Rotshenker S (1996) Granulocyte macrophage colony stimulating factor produced in lesioned peripheral nerves induces the upregulation of cell surface expression of MAC-2 by macrophages and Schwann cells. J Cell Biol 133: 159-167
95. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222
96. Sanz N, Diez-Fernandez C, Alvarez A, Cascales M (1997) Age-dependent modifications in rat hepatocyte antioxidant defense systems. J Hepatol 27: 525-534
97. Sayre LM, Arora PK, Iyer RS, Salomon RG (1993) Pyrrole formation from 4-hydroxynonenal and primary amines. Chem Res Toxicol 6: 19-22
98. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimers disease. J Neurochem 68: 2092-2097
99. Schmidt AM, Yan SD, Brett J, Mora R, Nowygrod R, Stern D (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest 91: 2155-2168
100. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscier Thromb 14: 1521-1528
101. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogaea S, Kuwabara K, Matsumoto M, Stern D (1996) RAGE, a novel cellular receptor for advanced glycation endproducts. Diabetes 45: 77-80
102. Schweers O, Mandelkow EM, Biernat J, Mandelkow E (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci USA 92: 8463-8467
103. Sheu KFR, Cooper AJL, Koike K, Koike M, Lindsay JG, Blass JP (1994) Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimers disease. Ann Neurol 35: 312-318
104. Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, Oimomi M, Kasuga M (1997) Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 138: 1886-1892
105. Simm A, Münch G, Seif F, Schenk O, Heidland A, Richter H, Vamvakas S, Schinzel R (1997) Advanced glycation endproducts activate the MAP kinase pathway in the tubulus cell line LLC-PK1. FEBS Lett 410: 481-484
106. Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S (1997) Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 322: 567-573
107. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994a) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimers disease. Am J Pathol 145: 42-47
108. Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G (1994b) Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimers disease. Ann NY Acad Sci 738: 447-454
109. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G (1994c) Advanced Maillard reaction end products are associated with Alzheimer disase pathology. Proc Natl Acad Sci USA 91: 5710-5714
110. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci 18: 172-176
111. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996a) Oxidative damage in Alzheimers. Nature 382: 120-121
112. Smith MA, Sayre LM, Perry G (1996b) Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia 39: 247
113. Smith MA, Harris PLR, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94: 9866-9868
114. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91: 4766-4770
115. Vlassara H, Brownlee M, Manogue K, Dinarello C, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240: 1546-1550
116. Vlassara H, Moldawer L, Chan B (1989) Macrophage/monocyte receptor for nonenzymatically glycosylated proteins is upregulated by cachectin/tumor necrosis factor. J Clin Invest 84: 1831-1820
117. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, Cerami A (1995) Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1: 634-646
118. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci USA 91: 7742-7746
119. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW (1995a) Mechanism of autoxidative glycosylation - identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochem 34: 3702-3709
120. Wells-Knecht MC, Thorpe SR, Baynes JW (1995b) Pathways of formation of glycoxidation products during glycation of collagen. Biochem 34: 15134-15141
121. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen SH, Stern D (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91: 7787-7791
122. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Stern D (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nature Med 1: 693-9
123. Yan SD, Chen X, Fu J, Chen M, Zhu HJ, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimers disease. Nature 382: 685-691
124. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, Suthanthiran M, Vlassara H (1991) Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 174: 515-524
125. 2 generation. J Neurochem 67: 1595-1606